{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:10:03Z","timestamp":1783620603387,"version":"3.55.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"RGC and HMRF"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>The risk of cardiovascular events (CVEs) with alendronate use in real-world hip fracture patients is unknown. This study aimed to investigate the risk of CVE with and without use of alendronate in patients with hip fracture. We conducted a retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority. Patients newly diagnosed with hip fracture from 2005 through 2013 were followed until November 6, 2016. Alendronate and other antiosteoporosis medications use during the study period were examined. We matched treated and nontreated patients based on time-dependent propensity score. The risks of cardiovascular mortality, myocardial infarction, and stroke between treatment groups were evaluated using conditional Cox regression stratified by match pairs. To examine the associations over time, outcomes were assessed at 1 year, 3 years, 5 years, and 10 years. Among 34,991 patients with newly diagnosed hip fracture, 4602 (13.2%) received antiosteoporosis treatment during follow-up. Physical functioning or survival prospect was not significantly different between treated and nontreated patients. A total of 4594 treated patients were matched with 13,568 nontreated patients. Results of Cox regression analysis revealed that alendronate was associated with a significantly lower risk of 1-year cardiovascular mortality (HR 0.33; 95% CI, 0.17 to 0.65) and incident myocardial infarction (HR 0.55; 95% CI, 0.34 to 0.89), whereas marginally significant reduction in risk of stroke was observed at 5 years and 10 years (HR at 5 years: 0.82; 95% CI, 0.67 to 1.00; p\u2009=\u20090.049; HR at 10 years: 0.83; 95% CI, 0.69 to 1.01; p\u2009=\u20090.065). The strength of the association declined over time but remained significant. Similar results were observed when all nitrogen-containing bisphosphonates (N-BPs) were analyzed together. These findings were robust in multiple sensitivity analyses. Additional studies in other population samples and randomized clinical trials may be warranted to further understand the relationship between use of various antiosteoporosis medication and risk of CVE in patients with hip fracture. \u00a9 2018 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.3448","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T06:00:16Z","timestamp":1525932016000},"page":"1422-1434","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture"],"prefix":"10.1093","volume":"33","author":[{"given":"Chor-Wing","family":"Sing","sequence":"first","affiliation":[{"name":"Department of Pharmacology and PharmacyLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel YS","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and PharmacyLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas P","family":"Kiel","sequence":"additional","affiliation":[{"name":"Institute for Aging ResearchHebrew SeniorLife and Department of Medicine Beth Israel Deaconess Medical Center and Harvard Medical SchoolBostonUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine YN","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Medicine and GeriatricsUnited Christian HospitalKwun TongHong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne KY","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of MedicineQueen Mary HospitalPokfulamHong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy T","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of MedicineLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther W","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and PharmacyLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie WC","family":"Kung","sequence":"additional","affiliation":[{"name":"Department of MedicineLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian CK","family":"Wong","sequence":"additional","affiliation":[{"name":"Research Department of Practice and PolicySchool of PharmacyUniversity College LondonLondonUK"},{"name":"Department of Pharmacology and PharmacyLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Lung","family":"Cheung","sequence":"additional","affiliation":[{"name":"Centre for Genomic SciencesLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong"},{"name":"The State Key Laboratory of Pharmaceutical BiotechnologyLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong"},{"name":"Department of MedicineLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong"},{"name":"Department of Pharmacology and PharmacyLi Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"issue":"2","key":"2024021014314918600_jbmr3448-bib-0001","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/jbmr.1714","article-title":"Hip fracture and risk of acute myocardial infarction: a nationwide study","volume":"28","author":"Chiang","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024021014314918600_jbmr3448-bib-0002","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/STROKEAHA.110.595538","article-title":"Increased risk of stroke in the year after a hip fracture: a population-based follow-up study","volume":"42","author":"Kang","year":"2011","journal-title":"Stroke"},{"issue":"4","key":"2024021014314918600_jbmr3448-bib-0003","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1359\/jbmr.091029","article-title":"Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study","volume":"25","author":"Cameron","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024021014314918600_jbmr3448-bib-0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1359\/jbmr.090704","article-title":"Potential mediators of the mortality reduction with zoledronic acid after hip fracture","volume":"25","author":"Colon-Emeric","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2024021014314918600_jbmr3448-bib-0005","year":"2017"},{"issue":"8","key":"2024021014314918600_jbmr3448-bib-0006","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/jbmr.2832","article-title":"Impact of the U.S. Food and Drug Administration's safety-related announcements on the use of bisphosphonates after hip fracture","volume":"31","author":"Kim","journal-title":"J Bone Miner Res. 2016"},{"issue":"21","key":"2024021014314918600_jbmr3448-bib-0007","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jacc.2010.05.050","article-title":"Bisphosphonate use and prevalence of valvular and vascular calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis)","volume":"56","author":"Elmariah","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2024021014314918600_jbmr3448-bib-0008","doi-asserted-by":"crossref","first-page":"269613","DOI":"10.1155\/2014\/269613","article-title":"Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients","volume":"2014","author":"Okamoto","year":"2014","journal-title":"J Transplant"},{"issue":"3","key":"2024021014314918600_jbmr3448-bib-0009","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/cvr\/cvs347","article-title":"Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice","volume":"97","author":"Yang","year":"2013","journal-title":"Cardiovasc Res"},{"issue":"3","key":"2024021014314918600_jbmr3448-bib-0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.biocel.2012.12.016","article-title":"Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo","volume":"45","author":"Yang","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"2024021014314918600_jbmr3448-bib-0011","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis"},{"issue":"9","key":"2024021014314918600_jbmr3448-bib-0012","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00198-010-1444-6","article-title":"Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study","volume":"22","author":"Sambrook","year":"2011","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024021014314918600_jbmr3448-bib-0013","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00198-015-3415-4","article-title":"Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study","volume":"27","author":"Brozek","year":"2016","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024021014314918600_jbmr3448-bib-0014","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1006\/rtph.2002.1550","article-title":"Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study","volume":"35","author":"Steinbuch","year":"2002","journal-title":"Regul Toxicol Pharmacol"},{"issue":"10","key":"2024021014314918600_jbmr3448-bib-0015","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrendo.2014.125","article-title":"Fracture mortality: associations with epidemiology and osteoporosis treatment","volume":"10","author":"Sattui","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"2024021014314918600_jbmr3448-bib-0016","doi-asserted-by":"crossref","first-page":"h6926","DOI":"10.1136\/bmj.h6926","article-title":"Cardiovascular outcomes associated with use of clarithromycin: population based study","volume":"352","author":"Wong","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"2024021014314918600_jbmr3448-bib-0017","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jamainternmed.2016.1586","article-title":"Association between acute neuropsychiatric events and Helicobacter pylori therapy containing clarithromycin","volume":"176","author":"Wong","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"11","key":"2024021014314918600_jbmr3448-bib-0018","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2017.1363","article-title":"Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation","volume":"317","author":"Lau","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"2024021014314918600_jbmr3448-bib-0019","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1517\/17425255.4.11.1371","article-title":"Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment","volume":"4","author":"Allen","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"2024021014314918600_jbmr3448-bib-0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S8756-3282(03)00112-1","article-title":"Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal","volume":"33","author":"Bagger","year":"2003","journal-title":"Bone"},{"issue":"11","key":"2024021014314918600_jbmr3448-bib-0021","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"key":"2024021014314918600_jbmr3448-bib-0022","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"Levesque","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"2024021014314918600_jbmr3448-bib-0023","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2024021014314918600_jbmr3448-bib-0024","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1541-0420.2005.00356.x","article-title":"Propensity score matching with time-dependent covariates","volume":"61","author":"Lu","year":"2005","journal-title":"Biometrics"},{"issue":"6)","key":"2024021014314918600_jbmr3448-bib-0025","doi-asserted-by":"crossref","first-page":"e015735","DOI":"10.1136\/bmjopen-2016-015735","article-title":"Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans","volume":"7","author":"Xie","year":"2017","journal-title":"BMJ Open"},{"key":"2024021014314918600_jbmr3448-bib-0026","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jcrc.2016.07.017","article-title":"Immortal time bias in observational studies of time-to-event outcomes","volume":"36","author":"Jones","year":"2016","journal-title":"J Crit Care"},{"issue":"8 Suppl","key":"2024021014314918600_jbmr3448-bib-0027","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2024021014314918600_jbmr3448-bib-0028","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/sim.4780030106","article-title":"A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias","volume":"3","author":"Simon","year":"1984","journal-title":"Stat Med"},{"issue":"8","key":"2024021014314918600_jbmr3448-bib-0029","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/jbmr.2888","article-title":"A crisis in the treatment of osteoporosis","volume":"31","author":"Khosla","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024021014314918600_jbmr3448-bib-0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mayocp.2013.08.021","article-title":"Myocardial infarction risk among patients with fractures receiving bisphosphonates","volume":"89","author":"Pittman","year":"2014","journal-title":"Mayo Clinic Proc"},{"key":"2024021014314918600_jbmr3448-bib-0031","doi-asserted-by":"crossref","first-page":"i493","DOI":"10.1136\/bmj.i493","article-title":"Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey","volume":"352","author":"Hemkens","year":"2016","journal-title":"BMJ"},{"issue":"15","key":"2024021014314918600_jbmr3448-bib-0032","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/eurheartj\/ehs114","article-title":"Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes","volume":"33","author":"Dahabreh","year":"2012","journal-title":"Eur Heart J"},{"issue":"7557","key":"2024021014314918600_jbmr3448-bib-0033","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.38875.675486.55","article-title":"A meta-analysis of the association between adherence to drug therapy and mortality","volume":"333","author":"Simpson","year":"2006","journal-title":"BMJ"},{"issue":"5","key":"2024021014314918600_jbmr3448-bib-0034","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.21404","article-title":"Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies","volume":"44","author":"Sorensen","year":"2006","journal-title":"Hepatology"},{"key":"2024021014314918600_jbmr3448-bib-0035","doi-asserted-by":"crossref","first-page":"e2809","DOI":"10.1136\/bmj.e2809","article-title":"Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review","volume":"344","author":"Akl","year":"2012","journal-title":"BMJ"},{"issue":"18","key":"2024021014314918600_jbmr3448-bib-0036","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2024021014314918600_jbmr3448-bib-0037","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-013-2582-4","article-title":"Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD","volume":"25","author":"Cooper","year":"2014","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024021014314918600_jbmr3448-bib-0038","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00198-013-2469-4","article-title":"Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate","volume":"25","author":"Abrahamsen","year":"2014","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024021014314918600_jbmr3448-bib-0039","first-page":"252","article-title":"Effects of bisphosphonates on lipid metabolism","volume":"29","author":"Guney","year":"2008","journal-title":"Neuro Endocrinol Lett"},{"issue":"2","key":"2024021014314918600_jbmr3448-bib-0040","doi-asserted-by":"crossref","first-page":"C248","DOI":"10.1152\/ajpcell.00393.2004","article-title":"Bisphosphonates stimulate an endogenous nonselective cation channel in Xenopus oocytes: potential mechanism of action","volume":"289","author":"Shao","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"2024021014314918600_jbmr3448-bib-0041","doi-asserted-by":"crossref","first-page":"G576","DOI":"10.1152\/ajpgi.00014.2002","article-title":"Physiological and morphological effects of alendronate on rabbit esophageal epithelium","volume":"283","author":"Dobrucali","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2024021014314918600_jbmr3448-bib-0042","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yjmcc.2016.08.017","article-title":"Vascular action of bisphosphonates: in vitro effect of alendronate on the regulation of cellular events involved in vessel pathogenesis","volume":"100","author":"Cutini","year":"2016","journal-title":"J Mol Cell Cardiol"},{"issue":"27","key":"2024021014314918600_jbmr3448-bib-0043","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.2174\/138161210793563626","article-title":"Alternative use of bisphosphonate therapy for rheumatic disease","volume":"16","author":"Le Goff","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"1","key":"2024021014314918600_jbmr3448-bib-0044","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000369693","article-title":"Pamidronate attenuates diastolic dysfunction induced by myocardial infarction associated with changes in geometric patterning","volume":"35","author":"Goncalves","year":"2015","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"2024021014314918600_jbmr3448-bib-0045","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"2024021014314918600_jbmr3448-bib-0046","year":"2017"},{"issue":"8","key":"2024021014314918600_jbmr3448-bib-0047","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/pds.4208","article-title":"Validity of major osteoporotic fracture diagnosis codes in the Clinical Data Analysis and Reporting System in Hong Kong","volume":"26","author":"Sing","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024021014314918600_jbmr3448-bib-0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2017.12.007","article-title":"Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: a systematic review and meta-analysis","volume":"86","author":"Man","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"issue":"10","key":"2024021014314918600_jbmr3448-bib-0049","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamapsychiatry.2017.2183","article-title":"Association of risk of suicide attempts with methylphenidate treatment","volume":"74","author":"Man","year":"2017","journal-title":"JAMA Psychiatry"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/8\/1422\/56649013\/jbmr3448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/8\/1422\/56649013\/jbmr3448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:01:46Z","timestamp":1710342106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/33\/8\/1422-1434\/7605120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,5,9]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3448","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8,1]]},"published":{"date-parts":[[2018,5,9]]},"assertion":[{"value":"2017-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}